CA 170
Advanced Solid Tumors or Lymphomas
Curis, Inc.Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Advanced Solid Tumors or Lymphomas cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
js019 Suzhou Kebo Ruijun Biotechnology Co., Ltd | Phase 1 | CC |
Nhwd-870 Hunan Province Tumor Hospital | D |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →